Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma

• Status: Unknown status
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Treatments: Endostatins

Criteria

Inclusion Criteria:

• Diagnosed metastatic NPC patient who have received radiotherapy or chemoradiotherapy with an at least 6 months interval

• Have measurable lesions

• No dysfunction of the major organs

• Can understand this study and give a signed informed consent certificates

• without a history of allergic reaction to the biological agents

Exclusion Criteria:

• Pregnant or lactating women; Women of child-bearing age without contraception

• with a Serious infection or dysfunction of the major organs

• have taken other antitumor drugs during the period of 30 days ahead of this clinical trial

• allergic to the Escherichia coli preparations

• Cann't understand this study and give a signed informed consent certificates